Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer
Joint Authors
Fu, Bo
Yan, Peng
Zhang, Shan
Lu, Yan
Pan, Li
Tang, Wenqiang
Chen, Shen
Chen, Shuangfeng
Zhang, Anqi
Liu, Wei
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-04-23
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Identification of early-stage tumor and monitoring therapeutic efficacy and recurrence or metastasis of colorectal cancer (CRC) are urgently warranted for improving the outcome of CRC patients and reducing the disease-related mortality.
In this study, we evaluated the diagnostic value of cell-free circulating methylated SEPT9 (mSEPT9) for CRC and beyond CRC and examined the potentiality of mSEPT9 in assessing therapeutic efficacy and monitoring recurrence of CRC.
Our results confirmed the favorable diagnostic value of plasma mSEPT9 for CRC, with a sensitivity of 61.22% (95% confidence interval (CI): 51.33%–70.27%) and specificity of 93.7% (95% CI: 91.09%–95.57%) using 2/3 algorithm.
The positive rate of mSEPT9 in CRC was correlated with tumor size, histological grade, and general histological type (P<0.05).
Beyond CRC, gastric cancer patients also presented a high positive rate of plasma mSEPT9 (70%).
The conversions between preoperative and postoperative plasma mSEPT9 reflected the therapeutic efficacy of curatively intended surgery for CRC patients.
The persistent positivity of plasma mSEPT9 after surgery (within 7–14 days) was highly associated with impending recurrences or metastases (within one year), with a sensitivity of 100%.
Postoperative mSEPT9 status during follow-up also provided valuable indication for CRC recurrence or metastases, with a good consistency (kappa = 0.818, P=0.001).
Our results verified the reliability of plasma mSEPT9 as a biomarker for noninvasive diagnosis of CRC.
More significantly, we revealed its valuable role in appraising CRC therapeutic efficacy and monitoring CRC recurrences or metastases.
Further studies with larger sample sizes are needed to verify and elucidate the clinical utility of the promising findings.
American Psychological Association (APA)
Fu, Bo& Yan, Peng& Zhang, Shan& Lu, Yan& Pan, Li& Tang, Wenqiang…[et al.]. 2018. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. Disease Markers،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1153508
Modern Language Association (MLA)
Fu, Bo…[et al.]. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. Disease Markers No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1153508
American Medical Association (AMA)
Fu, Bo& Yan, Peng& Zhang, Shan& Lu, Yan& Pan, Li& Tang, Wenqiang…[et al.]. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. Disease Markers. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1153508
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1153508